Literature DB >> 3664530

Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseases.

G De Rossi1, G De Sanctis, V Bottari, M Tribalto, M Lopez, M T Petrucci, L Fontana.   

Abstract

To determine whether monoclonal gammopathy of undetermined significance (MGUS) resembles multiple myeloma (MM) with regard to phenotype and functional activity, 16 patients with MGUS and 16 with untreated MM were studied for surface markers and cytotoxic activities phytohemagglutinin-induced cellular cytotoxicity (PHA-ICC), antibody-dependent cellular cytotoxicity, natural killer (NK) activity. Our data showed a consistent immunological similarity between the two diseases. An increase in OKT8+ cells was evident in both patient groups and a significant reduction in the T4/T8 ratio, more pronounced in MM, was observed. Alterations in NK activity or ADCC were not found in MGUS or MM. A significant increase in PHA-ICC was demonstrated in the two diseases. The increase in PHA-ICC observed seems to be attributable to an increased frequency and/or lytic efficiency of PHA-ICC lymphoid effector cells. These data suggest that similar immunological alterations are common to the two diseases. The greater helper/suppressor ratio reduction observed in MM seems to be related to the more severe clonal proliferation in these patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664530     DOI: 10.1007/bf00199953

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Mitogen induced cellular cytotoxicity (MICC) in multiple myeloma.

Authors:  D M Yonkosky; S L Silverman; E S Cathcart
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

2.  In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities.

Authors:  H Mellstedt; G Holm
Journal:  Clin Exp Immunol       Date:  1973-11       Impact factor: 4.330

Review 3.  Monoclonal gammopathy of undetermined significance (MGUS): a review.

Authors:  R A Kyle
Journal:  Clin Haematol       Date:  1982-02

4.  Cell membrane markers in acute lymphoid leukemia in relapse.

Authors:  G De Rossi; C Guglielmi; D Pasqualetti; M Lopez; F Mandelli
Journal:  Biomedicine       Date:  1981-10

5.  Subpopulations of T-lymphocytes in multiple myeloma.

Authors:  A Pezzutto; G Semenzato; C Agostini; R Raimondi; G Gasparotto
Journal:  Scand J Haematol       Date:  1981-04

6.  T-cell subpopulations in multiple myeloma: correlation with clinical disease status.

Authors:  M M Oken; N E Kay
Journal:  Br J Haematol       Date:  1981-12       Impact factor: 6.998

7.  Decreased NK activity in hairy cell leukemia (HCL): an analysis at the cellular level.

Authors:  L Fontana; G De Rossi; G De Sanctis; F Ensoli; M Lopez; L Annino; F Mandelli
Journal:  Blut       Date:  1986-08

8.  T-cell subsets in malignant lymphomas and monoclonal gammopathies.

Authors:  L Bergmann; P S Mitrou; W Kelker; K C Weber
Journal:  Scand J Haematol       Date:  1985-02

9.  Imbalances of T-cell subsets in monoclonal gammopathies.

Authors:  L Bergmann; P S Mitrou; K C Weber; W Kelker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  PHA-ICC, ADCC and NK in patients with ANLL in CR: human fibroblastic interferon fails to increase NK-active cell frequency.

Authors:  L Fontana; G De Rossi; G De Sanctis; V Bottari; G Avvisati; R Perricone; F Mandelli
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

View more
  9 in total

1.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

Review 2.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

3.  IgE myeloma with elevated level of serum CA125.

Authors:  Man-Ling Wang; Qiang Huang; Tian-Xin Yang
Journal:  J Zhejiang Univ Sci B       Date:  2009-07       Impact factor: 3.066

Review 4.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

Review 5.  Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Authors:  Masafumi Taniwaki; Mihoko Yoshida; Yosuke Matsumoto; Kazuho Shimura; Junya Kuroda; Hiroto Kaneko
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-02-15       Impact factor: 2.576

Review 6.  Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors:  Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 7.  The Immune Microenvironment in Multiple Myeloma: Friend or Foe?

Authors:  Raquel Lopes; Joana Caetano; Bruna Ferreira; Filipa Barahona; Emilie Arnault Carneiro; Cristina João
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

Review 8.  Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.

Authors:  Samuel S McCachren; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 9.  NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

Authors:  Renato Zambello; Gregorio Barilà; Sabrina Manni; Francesco Piazza; Gianpietro Semenzato
Journal:  Cells       Date:  2020-03-21       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.